New Chronic Kidney Disease Findings Has Been Reported by Investigators at Hannover Medical School (Renal Events In Patients Receiving Neprilysin Inhibitors: a Systematic Review and Meta-analysis).

A systematic review and meta-analysis conducted by investigators at Hannover Medical School in Germany examined the risk of renal events in patients receiving neprilysin inhibitors (NEPi) in combination with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) compared to ACEi or ARBs alone. The study included 17 randomized controlled trials involving a total of 23,569 patients. The findings showed that treatment with NEPi and ACEi/ARBs slightly lowered the risk of any renal event, severe acute renal events, and decline in estimated glomerular filtration rate. However, there was no difference in chronic renal events or hyperkalemia. The researchers concluded that longer trials focusing on chronic kidney disease are needed to further evaluate the effect of NEPi on decreasing disease progression. [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)